Epigenetic regulation is fundamental to the establishment and maintenance of cellular identity. Through DNA methylation, histone modifications, higher-order chromatin architecture and RNA-mediated mechanisms, it governs chromatin accessibility and transcriptional output, enabling cells with the same genome to adopt distinct functional states.
Published in Science China Life Sciences , the comprehensive review “Epigenetics in development, disease, and therapy: from mechanisms to clinical interventions” traces how epigenetic mechanisms establish, maintain, and reshape biological states across the lifespan—from fertilization and embryonic development to disease, regenerative medicine, and emerging
The epigenetic code behind cell identity
Epigenetic regulation allows cells with the same DNA to adopt different identities and functions. Through coordinated regulation of chromatin accessibility, genome organization and RNA metabolism, these mechanisms shape cell-type-specific patterns of gene expression. Working together, they help establish stable cellular programs while preserving the flexibility needed to respond to developmental signals and environmental changes. This balance between stability and adaptability is essential for normal development, tissue maintenance and regeneration.
This control is especially dynamic at the start of life. After the sperm and oocyte genomes unite, the embryo undergoes extensive but precisely timed epigenetic reprogramming. Some inherited marks are erased, others are retained, the zygotic genome becomes activated, and cells gradually transition from totipotency toward distinct developmental lineages. These coordinated changes help establish the developmental programs required for successful embryogenesis.
These insights also have important implications for reproductive medicine. The review discusses how parental age, environmental exposures, assisted-reproduction procedures and embryo culture conditions may influence the epigenetic state of gametes and early embryos, potentially affecting developmental outcomes. At the same time, the authors emphasize that such associations are highly context-dependent and require rigorous mechanistic and clinical validation before they can be used for prediction or therapeutic intervention.
Rewriting cell fate and protecting cell quality
The same logic applies when scientists try to reset a mature cell. Reprogramming a somatic cell into an induced pluripotent stem cell is not simply a matter of turning on a handful of genes. The cell must overcome established identity barriers, including DNA methylation, repressive histone marks such as H3K9me3, higher-order genome structure and residual epigenetic memory.
These barriers help explain why efficiency alone is not enough for regenerative medicine. The review discusses how more coordinated epigenetic remodeling could improve reprogramming and nuclear-transfer cloning, while noting the need to limit persistent memory, instability and other safety concerns before wider clinical use.
In adult tissues, epigenetic programs continue to support renewal, repair and specialized function. Examples from pancreatic beta cells, skeletal-muscle stem cells and hematopoietic stem cells illustrate how disruption of cell-identity networks can contribute to diabetes, muscle degeneration and blood disorders. Disease, in this view, can arise not only when cells are lost, but also when their functional programs become unstable.
When epigenetic control breaks down: aging and cancer
Aging is one context in which epigenetic instability can gradually accumulate. Over time, DNA methylation patterns drift, histone modifications and chromatin architecture are altered, and RNA regulation can become increasingly dysregulated. DNA methylation clocks now provide a means of estimating aspects of biological age, while small molecules, lifestyle interventions, senolytic strategies and partial cellular reprogramming are being explored for their potential to extend health span. The review cautions, however, that claims of rejuvenation require rigorous validation across tissues, populations and longer timescales.
Cancer provides another striking example of epigenetic dysregulation. Alongside genetic mutations, alterations in chromatin remodeling, DNA methylation, histone modifications and RNA modifications can enable tumor cells to sustain proliferation, adapt to metabolic stress, evade immune surveillance and resist therapy. The review therefore presents tumors not simply as collections of genetic mutations, but also as aberrant cellular states shaped and maintained by disrupted epigenetic programs.
From disease signals to therapeutic opportunities
Because epigenetic states are measurable, relatively stable and, in some cases, reversible, they provide multiple routes toward clinical translation. The review highlights three major directions: DNA-methylation-based biomarkers for disease detection, classification, prognosis and treatment monitoring; small-molecule drugs targeting proteins that write, read or erase epigenetic marks; and emerging epigenome-editing technologies designed to regulate selected genomic sites without altering the underlying DNA sequence.
Further advances in understanding epigenetic regulation during development and disease will help clarify how cellular identities are established and maintained, how cell fates change, and how pathological states emerge. These insights may also support new biomarkers, therapeutic targets and intervention strategies for applications such as early cancer detection and treatment stratification, embryo-quality assessment, and the monitoring and modulation of aging-related states.
Several challenges must be addressed before these approaches can be translated into wider clinical use. Delivery efficiency, cell-type specificity, durability, unintended effects and long-term safety require rigorous evaluation, particularly for interventions that may produce persistent changes or affect germ cells. As epigenetic research moves from mapping associations to establishing causal mechanisms and developing precise interventions, ethical oversight, clinical validation and regulatory frameworks will need to evolve in parallel.
Overall, the review presents an integrated, life-course perspective on epigenetic regulation, tracing how cellular states are established during development, maintained in adult tissues, disrupted in aging and disease, and potentially redirected through therapeutic intervention. By linking fundamental mechanisms with emerging applications, it outlines the scientific opportunities and translational challenges likely to shape the next phase of epigenetics.
Science China Life Sciences
Literature review